xml: <clinical_study>
    <!-- This xml conforms to an XML Schema at:
      https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
    <required_header>
      <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
      <link_text>Link to the current ClinicalTrials.gov record.</link_text>
      <url>https://clinicaltrials.gov/ct2/show/NCT05979675</url>
    </required_header>
    <id_info>
      <org_study_id>AML_Registry</org_study_id>
      <nct_id>NCT05979675</nct_id>
    </id_info>
    <brief_title>Acute Myeloid Leukemia Registry</brief_title>
    <acronym>AMLREGISTRY</acronym>
    <official_title>Acute Myeloid Leukemia Registry - Prospective National Multicentric Observational Study</official_title>
    <sponsors>
      <lead_sponsor>
        <agency>Turkish Hematology Association</agency>
        <agency_class>Other</agency_class>
      </lead_sponsor>
    </sponsors>
    <source>Turkish Hematology Association</source>
    <oversight_info>
      <has_dmc>No</has_dmc>
      <is_fda_regulated_drug>No</is_fda_regulated_drug>
      <is_fda_regulated_device>No</is_fda_regulated_device>
    </oversight_info>
    <brief_summary>
      <textblock>
        All acute myeloid leukemia (AML) patients diagnosed after 1 Jan 2020 will be included to this&#xD;
        study.&#xD;
      </textblock>
    </brief_summary>
    <detailed_description>
      <textblock>
        This is a non interventional prospective disease registry, 250 prospective patients diagnosed&#xD;
        with AML across 20 centers in Turkey.&#xD;
  &#xD;
        Participating sites will consist of hematology clinics and routine follow-up procedures will&#xD;
        be followed-up.&#xD;
  &#xD;
        All patients diagnosed after 1 Jan 2020 as AML will be included and patients will be enrolled&#xD;
        during 24 months of period and will be followed-up 36 months. Study will be completed in 60&#xD;
        months.&#xD;
      </textblock>
    </detailed_description>
    <overall_status>Recruiting</overall_status>
    <start_date type="Actual">December 21, 2021</start_date>
    <completion_date type="Anticipated">December 21, 2026</completion_date>
    <primary_completion_date type="Anticipated">December 21, 2026</primary_completion_date>
    <study_type>Observational [Patient Registry]</study_type>
    <has_expanded_access>No</has_expanded_access>
    <study_design_info>
      <observational_model>Cohort</observational_model>
      <time_perspective>Prospective</time_perspective>
    </study_design_info>
    <target_duration>24 Months</target_duration>
    <primary_outcome>
      <measure>Overall Survival</measure>
      <time_frame>60 months</time_frame>
      <description>From diagnosis to exits by any cause</description>
    </primary_outcome>
    <enrollment type="Anticipated">250</enrollment>
    <condition>Acute Myeloid Leukemia</condition>
    <eligibility>
      <study_pop>
        <textblock>
          All AML patients diagnosed after 1 Jan 2020 will be included to this study.&#xD;
        </textblock>
      </study_pop>
      <sampling_method>Non-Probability Sample</sampling_method>
      <criteria>
        <textblock>
          Inclusion Criteria:&#xD;
  &#xD;
            -  Diagnosed as AML after 1 Jan 2020&#xD;
  &#xD;
            -  Patients signed informed consent form&#xD;
  &#xD;
          Exclusion Criteria:&#xD;
  &#xD;
            -  Patients under 18 years old&#xD;
        </textblock>
      </criteria>
      <gender>All</gender>
      <minimum_age>18 Years</minimum_age>
      <maximum_age>N/A</maximum_age>
      <healthy_volunteers>No</healthy_volunteers>
    </eligibility>
    <overall_official>
      <last_name>Ilker Kurkcu</last_name>
      <role>Study Director</role>
      <affiliation>Sentez Cro</affiliation>
    </overall_official>
    <overall_contact>
      <last_name>Volkan Karakus, Assoc. Prof.</last_name>
      <phone>905057656778</phone>
      <email>dr_v_karakus@yahoo.com</email>
    </overall_contact>
    <overall_contact_backup>
      <last_name>Ilker Kurkcu</last_name>
      <phone>905326354515</phone>
      <email>ilker.kurkcu@sentez-cro.com</email>
    </overall_contact_backup>
    <location>
      <facility>
        <name>Antalya Training and Research Hospital</name>
        <address>
          <city>Antalya</city>
          <country>Turkey</country>
        </address>
      </facility>
      <status>Recruiting</status>
      <contact>
        <last_name>Volkan Karakus</last_name>
      </contact>
      <contact_backup>
        <email>dr_v_karakus@yahoo.com</email>
      </contact_backup>
      <investigator>
        <last_name>Volkan Karakus</last_name>
        <role>Principal Investigator</role>
      </investigator>
    </location>
    <location_countries>
      <country>Turkey</country>
    </location_countries>
    <verification_date>July 2023</verification_date>
    <study_first_submitted>July 29, 2023</study_first_submitted>
    <study_first_submitted_qc>July 29, 2023</study_first_submitted_qc>
    <study_first_posted type="Actual">August 7, 2023</study_first_posted>
    <last_update_submitted>July 29, 2023</last_update_submitted>
    <last_update_submitted_qc>July 29, 2023</last_update_submitted_qc>
    <last_update_posted type="Actual">August 7, 2023</last_update_posted>
    <responsible_party>
      <responsible_party_type>Sponsor</responsible_party_type>
    </responsible_party>
    <condition_browse>
      <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
      <mesh_term>Leukemia</mesh_term>
      <mesh_term>Leukemia, Myeloid</mesh_term>
      <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    </condition_browse>
    <patient_data>
      <sharing_ipd>No</sharing_ipd>
    </patient_data>
    <!-- Results have not yet been posted for this study                                          -->
  </clinical_study>
  
  
text: download date: ClinicalTrials.gov processed this data on September 20, 2023
  link text: Link to the current ClinicalTrials.gov record.
  url: https://clinicaltrials.gov/ct2/show/NCT05979675
  org study id: AML_Registry
  nct id: NCT05979675
  lead sponsor: 
  has dmc: No
  is fda regulated drug: No
  is fda regulated device: No
  All acute myeloid leukemia (AML) patients diagnosed after 1 Jan 2020 will be included to this
        study.
  This is a non interventional prospective disease registry, 250 prospective patients diagnosed
        with AML across 20 centers in Turkey.
  
        Participating sites will consist of hematology clinics and routine follow-up procedures will
        be followed-up.
  
        All patients diagnosed after 1 Jan 2020 as AML will be included and patients will be enrolled
        during 24 months of period and will be followed-up 36 months. Study will be completed in 60
        months.
  observational model: Cohort
  time perspective: Prospective
  measure: Overall Survival
  time frame: 60 months
  description: From diagnosis to exits by any cause
  study pop: 
  sampling method: Non-Probability Sample
  criteria: 
  gender: All
  minimum age: 18 Years
  maximum age: N/A
  healthy volunteers: No
  last name: Ilker Kurkcu
  role: Study Director
  affiliation: Sentez Cro
  last name: Volkan Karakus, Assoc. Prof.
  phone: 905057656778
  email: dr_v_karakus@yahoo.com
  last name: Ilker Kurkcu
  phone: 905326354515
  email: ilker.kurkcu@sentez-cro.com
  facility: 
  status: Recruiting
  contact: 
  contact backup: 
  investigator: 
  country: Turkey
  responsible party type: Sponsor
  mesh term: Leukemia
  mesh term: Leukemia, Myeloid
  mesh term: Leukemia, Myeloid, Acute
  sharing ipd: No